This article is more than 5 years old. Information may no longer be current.
Allergan, Acadia extend partnership
Click Here to Manage Email Alerts
SAN DIEGO — Acadia Pharmaceuticals will continue its drug discovery collaboration with Allergan through at least 2013, the company announced in a press release.
The companies' combined efforts, which began in 2003, are focused on discovering new therapeutics for glaucoma and other ophthalmic indications, the release said.
Under the agreement, Allergan gains exclusive license to specified chemistry and related assets for development and commercialization, while Acadia receives research funding and may receive license fees and milestone payments related to clinical and regulatory objectives, according to the release. Acadia also may earn royalties on product sales related to the agreement.
Acadia has two additional collaboration agreements with Allergan, the release said. Those agreements previously have led to clinical programs related to glaucoma and chronic pain.